Pharmacokinetics and pharmacodynamics in HAART and antibiotic therapy

New Microbiologica

Volumn 30, Issue 3, 2007, Pages 346-349

  Boffito, Marta ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral drugs; Drug interactions; HIV infection; Pharmacology

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT;

ARTICLE; DRUG INTERACTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM;

ANTI-BACTERIAL AGENTS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34547941598     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. ANDERSON, P.L., KAKUDA, T.N., KAWLE, S., FLETCHER, C.V. (2003) Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate con centrations in HIV-infected individuals. AIDS. 17, 2159-2168.
2. BOFFITO, M., ACOSTA, E., BURGER, D., FLETCHER, C.V., FLEXNER, C., GARAFFO, R., GATTI, G., KUROWSKI, M., PERNO, C.F., PEYTAVIN, G., REGAZZI, M., BACK, D. (2005) Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir Ther. 10, 375-392.
3. FICHTENBAUM, C.J., GERBER, J.G. (2002) Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 41, 1195-1211.
4. GAZZARD, B., BERNARD, A.J., BOFFITO, M., CHURCHILL, D., EDWARDS, S., FISHER, N., GERETTI, A.M., JOHNSON, M., LEEN, C., PETERS, B., POZNIAK, A., ROSS, J., WALSH, J., WILKINS, E., YOULE, M., WRITING COMMITTEE, BRITISH HIV ASSOCIATION. (2006) British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 7, 487-503.
5. KALETRA®. Lopinavir/ritonavir capsules/tablets. Summary of Product Characteristics. Abbott Laboratories, North Chicago, IL, USA. July 2006.
6. LEXIVA®. Fosamprenavir tablets. Summary of Product Characteristics. GlaxoSmithKline, Research Triangle Park, NC, USA. July 2005.
7. LUBER, A., GARG, V., GHARAKHANAIN, S. (2004). Survey mediaction used by HIV-infected patients that affect gastrointestinal (GI) acidity and potential for negative drug interactions with HAART. 7th International Congress on Drug Therapy in HIV infection. 14-18 November, Glasgow, UK. Abstr. P206.
8. MATHEWS, W.C., MCCUTCHAN, J.A., ASCH, S., TURNER, B.J., GIFFORD, A.L., KUROMIYA, K., BROWN, J., SHAPIRO, M.F., BOZZETTE, S.A. (2000) National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization Study. Med Care. 38, 750-762.
9. NEUMAN, M.G., MONTEIRO, M., REHM, J. (2006) Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses. Subst Use Misuse. 41, 1395-1463.
10. SHELTON, M.J., FORD, S.L., BORLAND, J., LOU, Y., WIRE, M.B., MIN, S.S., XUE, Z.G., YUEN, G. (2006) Coadministration of esomeprazole with fosamprenavir has no impact on steady-state plasma amprenavir pharmacokinetics. J Acquir Immune Defic Syndr. 42, 61-67.